Abstract：
Resistance of SARS-CoV-2 to antivirals was shown to develop in immunocompromised individuals receiving remdesivir. We describe an immunocompromised patient who was treated with repeated and prolonged courses of nirmatrelvir and developed de-novo E166V/L50F mutations in the Mpro region. These mutations were associated with clinical and virological treatment failure.
摘要：
在接受remdesivir的免疫受损个体中显示出SARS-CoV-2对抗病毒药物的抗性。我们描述了一名免疫功能低下的患者，该患者接受了反复和长时间的nirmatrelvir疗程治疗，并在Mpro区域发生了从头E166V/L50F突变。这些突变与临床和病毒学治疗失败有关。
